MAP2K1 and melanoma: The results so far suggest that some mutations in the MAP2K1 and MAP2K2 genes may contribute to the primary resistance of melanoma cells to targeted therapy and should be further investigated both functionally and in clinics as a part of the genetic predictive panel.